In the past week, HRMY stock has gone up by 2.05%, with a monthly gain of 11.71% and a quarterly surge of 26.40%. The volatility ratio for the week is 3.73%, and the volatility levels for the last 30 days are 3.49% for Harmony Biosciences Holdings Inc. The simple moving average for the past 20 days is 6.58% for HRMY’s stock, with a 23.00% simple moving average for the past 200 days.
Is It Worth Investing in Harmony Biosciences Holdings Inc (NASDAQ: HRMY) Right Now?
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) has a higher price-to-earnings ratio of 20.37x compared to its average ratio, The 36-month beta value for HRMY is at 0.73. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 2 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for HRMY is 30.70M, and currently, shorts hold a 27.40% of that float. The average trading volume for HRMY on September 27, 2024 was 392.98K shares.
HRMY) stock’s latest price update
The stock price of Harmony Biosciences Holdings Inc (NASDAQ: HRMY) has jumped by 6.70 compared to previous close of 37.29. Despite this, the company has seen a gain of 2.05% in its stock price over the last five trading days. prnewswire.com reported 2024-09-26 that PLYMOUTH MEETING, Pa., Sept. 26, 2024 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), will provide an overview of its robust, late-stage pipeline at an in-person Investor Day at 8:30 a.m.
Analysts’ Opinion of HRMY
Many brokerage firms have already submitted their reports for HRMY stocks, with UBS repeating the rating for HRMY by listing it as a “Buy.” The predicted price for HRMY in the upcoming period, according to UBS is $56 based on the research report published on September 10, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see HRMY reach a price target of $48. The rating they have provided for HRMY stocks is “Buy” according to the report published on June 21st, 2024.
BofA Securities gave a rating of “Underperform” to HRMY, setting the target price at $30 in the report published on January 02nd of the current year.
HRMY Trading at 12.43% from the 50-Day Moving Average
After a stumble in the market that brought HRMY to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 0.15% of gains for the given period.
Volatility was left at 3.49%, however, over the last 30 days, the volatility rate increased by 3.73%, as shares surge +12.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.28% upper at present.
During the last 5 trading sessions, HRMY rose by +2.05%, which changed the moving average for the period of 200-days by +28.35% in comparison to the 20-day moving average, which settled at $37.55. In addition, Harmony Biosciences Holdings Inc saw 23.19% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HRMY starting from Dierks Jeffrey, who sale 11,979 shares at the price of $32.00 back on Mar 15 ’24. After this action, Dierks Jeffrey now owns 0 shares of Harmony Biosciences Holdings Inc, valued at $383,328 using the latest closing price.
Dierks Jeffrey, the CHIEF COMMERCIAL OFFICER of Harmony Biosciences Holdings Inc, sale 194 shares at $32.00 during a trade that took place back on Mar 08 ’24, which means that Dierks Jeffrey is holding 0 shares at $6,208 based on the most recent closing price.
Stock Fundamentals for HRMY
Current profitability levels for the company are sitting at:
- 0.27 for the present operating margin
- 0.78 for the gross margin
The net margin for Harmony Biosciences Holdings Inc stands at 0.18. The total capital return value is set at 0.25. Equity return is now at value 22.46, with 14.21 for asset returns.
Based on Harmony Biosciences Holdings Inc (HRMY), the company’s capital structure generated 0.29 points at debt to capital in total, while cash flow to debt ratio is standing at 0.98. The debt to equity ratio resting at 0.41. The interest coverage ratio of the stock is 6.53.
Currently, EBITDA for the company is 231.28 million with net debt to EBITDA at -0.45. When we switch over and look at the enterprise to sales, we see a ratio of 3.3. The receivables turnover for the company is 7.89for trailing twelve months and the total asset turnover is 0.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.13.
Conclusion
In conclusion, Harmony Biosciences Holdings Inc (HRMY) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
